Antibody Response to Generex’s AE37 Breast Cancer Vaccine Allows Reduced Relapse

Antibody Response to Generex’s AE37 Breast Cancer Vaccine Allows Reduced Relapse
shutterstock_174170939At the 29th Annual Meeting & Associated Programs of the Society for Immunotherapy of Cancer held November 6-9, a representative from Generex Biotechnology Corporation presented data detailing proof of concept for the company's AE37 cancer vaccine developed by subsidiary Antigen Express, Inc. The vaccine induces an antibody response to HER2, the target of AE37, and reduces relapse in breast cancer patients. The presentation, "Correlation of HER2/neu Antibody Response to Clinical Response in a Phase II Trial of the AE37+GM-CSF HER2 Peptide Vaccine," demonstrated that antibody response, not necessarily absolute levels of HER2-specific antibody, allowed relapse in enrolled patients. According to a news release from the company, this is the first study to characterize HER2-specific antibody response induced by the AE37 vaccine. The AE37 peptid
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.